Sarilumab
Sanofi,regeneron
[]
spiera et al. resolution pmr in saphyr trial il-6i sarilumab. week 52, 81% vs 57% with no signs/symptoms more in pbo arm needed rescue gcs 58.6% vs 32.2% #acr22 abstr#1543 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC